Entyvio vs Stelara
Vedolizumab vs Ustekinumab · Comparison Guide
Quick Comparison
| Feature | Entyvio | Stelara |
|---|---|---|
| Generic Name | Vedolizumab | Ustekinumab |
| Manufacturer | Takeda | Janssen |
| Drug Class | Anti-integrin (gut-selective) | IL-12/23 Inhibitor |
| Shared Conditions | Ulcerative Colitis, Crohn's Disease | |
Key Differences: Entyvio vs Stelara
Both are preferred options for IBD. Entyvio is gut-selective (minimal systemic immune suppression), making it a preferred choice for patients with infection concerns or older patients. Stelara is systemic and covers Crohn's and UC equally. Head-to-head data from the VARSITY trial showed Entyvio superior to Humira for UC; no direct Entyvio vs Stelara head-to-head exists. Gastroenterologists often weigh gut-selectivity vs systemic IL-23 blockade based on individual patient factors.
💊 Entyvio (Vedolizumab)
- Class: Anti-integrin (gut-selective)
- Manufacturer: Takeda
- Full Entyvio information →
💊 Stelara (Ustekinumab)
- Class: IL-12/23 Inhibitor
- Manufacturer: Janssen
- Full Stelara information →
Both are preferred options for IBD. Entyvio is gut-selective (minimal systemic immune suppression), making it a preferred choice for patients with infection concerns or older patients. Stelara is systemic and covers Crohn's and UC equally. Head-to-head data from the VARSITY trial showed Entyvio superior to Humira for UC; no direct Entyvio vs Stelara head-to-head exists. Gastroenterologists often weigh gut-selectivity vs systemic IL-23 blockade based on individual patient factors.
Neither Entyvio nor Stelara is universally better — the right choice depends on your specific condition, disease severity, insurance formulary, and health history. Your prescriber will determine which is most appropriate based on your clinical situation. BiologicHealthPlus carries both and can help you compare your coverage and costs for either medication.
Switching between biologics is common. Your prescriber will evaluate your current treatment response and determine if a switch is appropriate. BiologicHealthPlus can coordinate the transition including prior authorization for your new medication.
Both Entyvio and Stelara are covered by most commercial insurance plans, Medicare Part D, and Medicaid with prior authorization. BiologicHealthPlus handles insurance verification and prior authorization for both medications at no charge. Most insured patients pay $0–$35/month through manufacturer copay programs.
Entyvio and Stelara both have high cash list prices ($4,000–$9,000/month range) but most commercially insured patients pay $0–$35/month through manufacturer savings programs. BiologicHealthPlus automatically enrolls every patient in all available savings programs at no charge.
✅ BiologicHealthPlus Carries Both Entyvio and Stelara
We handle insurance verification, prior authorization, copay enrollment, and free cold-chain delivery for both medications. Contact us and we'll help you understand your options and costs.
Medical Disclaimer: This comparison is for educational purposes only. The choice between Entyvio and Stelara should be made by your healthcare provider based on your specific medical history, disease severity, and individual circumstances. Last updated: July 2026.